Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Myeloma

Preserved levels of uninvolved immunoglobulins are independently associated with favorable outcome in patients with symptomatic multiple myeloma

Abstract

Suppression of uninvolved immunoglobulins is common in multiple myeloma (MM) but the prognostic significance of this phenomenon has not been assessed. We evaluated the prognostic significance of the preservation of uninvolved immunoglobulins in 1755 consecutive, unselected, patients with newly diagnosed, symptomatic MM with pre-therapy immunoglobulin levels measured by nephelometry. Suppression of at least one uninvolved immunoglobulin was observed in 87% of patients and was more common in patients with immunoglobulin A myeloma, those aged over 65 years, in patients with advanced-International Staging System (ISS) stage, extensive-bone marrow infiltration, anemia, low platelet counts, high levels of serum M-monoclonal protein or renal dysfunction. Patients with preserved immunoglobulins had a better survival than patients with suppressed immunoglobulins (median survival 55 vs 41.5 months, P<0.001). In multivariate analysis, preservation of uninvolved immunoglobulins was independently associated with better survival (hazard ratio: 0.781, 95% confidence interval: 0.618–0.987, P=0.039); irrespective of the treatment. In a subset of 500 patients, which were strictly followed for disease progression, preservation of uninvolved immunoglobulins was associated with a significantly longer progression-free survival (60 vs 25 months, P<0.001), independently of other common prognostic factors. In conclusion, preservation of uninvolved immunoglobulins in newly diagnosed patients with symptomatic MM was independently associated with long term disease control and improved survival.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Palumbo A, Anderson K . Multiple myeloma. N Engl J Med 2011; 364: 1046–1060.

    Article  CAS  Google Scholar 

  2. Pruzanski W, Gidon MS, Roy A . Suppression of polyclonal immunoglobulins in multiple myeloma: relationship to the staging and other manifestations at diagnosis. Clin Immunol Immunopathol 1980; 17: 280–286.

    Article  CAS  Google Scholar 

  3. Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003; 78: 21–33.

    Article  Google Scholar 

  4. Wang L, Young DC . Suppression of polyclonal immunoglobulin production by M-proteins shows isotype specificity. Ann Clin Lab Sci 2001; 31: 274–278.

    CAS  PubMed  Google Scholar 

  5. Alexanian R, Migliore PJ . Normal immunoglobulins in multiple myeloma: effect of melphalan chemotherapy. J Lab Clin Med 1970; 75: 225–233.

    CAS  PubMed  Google Scholar 

  6. Kawano M, Iwato K, Asaoku H, Tanabe O, Tanaka H, Ishikawa H et al. Altered cytokine activities are related to the suppression of synthesis of normal immunoglobulin in multiple myeloma. Am J Hematol 1989; 30: 91–96.

    Article  CAS  Google Scholar 

  7. Peltonen S, Wasastjerna C, Wager O . Clinical features of patients with a serum M component. Acta Med Scand 1978; 203: 257–263.

    Article  CAS  Google Scholar 

  8. Cesana C, Klersy C, Barbarano L, Nosari AM, Crugnola M, Pungolino E et al. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. J Clin Oncol 2002; 20: 1625–1634.

    Article  Google Scholar 

  9. Blade J, Dimopoulos M, Rosinol L, Rajkumar SV, Kyle RA . Smoldering (asymptomatic) multiple myeloma: current diagnostic criteria, new predictors of outcome, and follow-up recommendations. J Clin Oncol 2010; 28: 690–697.

    Article  CAS  Google Scholar 

  10. Kyle RA, Remstein ED, Therneau TM, Dispenzieri A, Kurtin PJ, Hodnefield JM et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med 2007; 356: 2582–2590.

    Article  CAS  Google Scholar 

  11. Kastritis E, Terpos E, Moulopoulos L, Spyropoulou-Vlachou M, Kanellias N, Eleftherakis-Papaiakovou E et al. Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease. Leukemia 2013; 27: 947–953.

    Article  CAS  Google Scholar 

  12. Katzmann JA, Clark R, Kyle RA, Larson DR, Therneau TM, Melton LJ 3rd et al. Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS. Leukemia 2013; 27: 208–212.

    Article  CAS  Google Scholar 

  13. Bradwell A, Harding S, Fourrier N, Mathiot C, Attal M, Moreau P et al. Prognostic utility of intact immunoglobulin Ig'kappa/Ig'lambda ratios in multiple myeloma patients. Leukemia 2013; 27: 202–207.

    Article  CAS  Google Scholar 

  14. Ashihara YKY, Nakamura RM . Immunoassays and immunochemistry. Henry's Clinical Diagnosis and Management by Laboratory Methods 22nd ed Saunders Elsevier: Philadelphia, PA, 2011.

    Google Scholar 

  15. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D . A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann Intern Med 1999; 130: 461–470.

    Article  CAS  Google Scholar 

  16. Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998; 102: 1115–1123.

    Article  CAS  Google Scholar 

  17. Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467–1473.

    Article  CAS  Google Scholar 

  18. Koulieris E, Panayiotidis P, Harding SJ, Kafasi N, Maltezas D, Bartzis V et al. Ratio of involved/uninvolved immunoglobulin quantification by Hevylite assay: clinical and prognostic impact in multiple myeloma. Exp Hematol Oncol 2012; 1: 9.

    Article  CAS  Google Scholar 

  19. Odendahl M, Mei H, Hoyer BF, Jacobi AM, Hansen A, Muehlinghaus G et al. Generation of migratory antigen-specific plasma blasts and mobilization of resident plasma cells in a secondary immune response. Blood 2005; 105: 1614–1621.

    Article  CAS  Google Scholar 

  20. Radbruch A, Muehlinghaus G, Luger EO, Inamine A, Smith KG, Dorner T et al. Competence and competition: the challenge of becoming a long-lived plasma cell. Nat Rev Immunol 2006; 6: 741–750.

    Article  CAS  Google Scholar 

  21. Chauhan D, Singh AV, Brahmandam M, Carrasco R, Bandi M, Hideshima T et al. Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target. Cancer Cell 2009; 16: 309–323.

    Article  CAS  Google Scholar 

  22. Gorgun GT, Whitehill G, Anderson JL, Hideshima T, Maguire C, Laubach J et al. Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans. Blood 2013; 121: 2975–2987.

    Article  CAS  Google Scholar 

  23. Asimakopoulos F, Kim J, Denu RA, Hope C, Jensen JL, Ollar SJ et al. Macrophages in multiple myeloma: emerging concepts and therapeutic implications. Leuk Lymphoma 2013; 54: 2112–2121.

    Article  Google Scholar 

  24. Braga WM, Atanackovic D, Colleoni GW . The role of regulatory T cells and TH17 cells in multiple myeloma. Clin Dev Immunol 2012; 2012: 293479.

    Article  Google Scholar 

  25. Broder S, Humphrey R, Durm M, Blackman M, Meade B, Goldman C et al. Impaired synthesis of polyclonal (non-paraprotein) immunoglobulins by circulating lymphocytes from patients with multiple myeloma Role of suppressor cells. N Engl J Med 1975; 293: 887–892.

    Article  CAS  Google Scholar 

  26. Waldmann TA, Broder S, Krakauer R, MacDermott RP, Durm M, Goldman C et al. The role of suppressor cells in the pathogenesis of common variable hypogammaglobulinemia and the immunodeficiency associated with myeloma. Fed Proc 1976; 35: 2067–2072.

    CAS  PubMed  Google Scholar 

  27. Ozer H, Han T, Henderson ES, Nussbaum A, Sheedy D . Immunoregulatory T cell function in multiple myeloma. J Clin Invest 1981; 67: 779–789.

    Article  CAS  Google Scholar 

  28. Tsujimoto T, Lisukov IA, Huang N, Mahmoud MS, Kawano MM . Plasma cells induce apoptosis of pre-B cells by interacting with bone marrow stromal cells. Blood 1996; 87: 3375–3383.

    CAS  PubMed  Google Scholar 

  29. Kawano MM, Mihara K, Huang N, Tsujimoto T, Kuramoto A . Differentiation of early plasma cells on bone marrow stromal cells requires interleukin-6 for escaping from apoptosis. Blood 1995; 85: 487–494.

    CAS  PubMed  Google Scholar 

  30. Peest D, Holscher R, Weber R, Leo R, Deicher H . Suppression of polyclonal B cell proliferation mediated by supernatants from human myeloma bone marrow cell cultures. Clin Exp Immunol 1989; 75: 252–257.

    CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Consortia

Corresponding author

Correspondence to M A Dimopoulos.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kastritis, E., Zagouri, F., Symeonidis, A. et al. Preserved levels of uninvolved immunoglobulins are independently associated with favorable outcome in patients with symptomatic multiple myeloma. Leukemia 28, 2075–2079 (2014). https://doi.org/10.1038/leu.2014.110

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2014.110

This article is cited by

Search

Quick links